About


 

Rapidscan Pharma Solutions (RPS, Inc.) was formed in 2010 by leading members of the team that discovered and developed regadenoson, a new pharmacological stress agent used in the diagnosis and risk stratification of cardiovascular disease.  RPS, Inc. has licensed the rights to sell regadenoson in Europe and other select territories.

Today, there are over 15M people in Europe with coronary artery disease, of which 1.5M patients undergo a myocardial perfusion imaging (MPI) procedure in the diagnosis of coronary artery disease (CAD).